Stellar Pharmaceuticals Inc. to Present at Global Hunter Investor Conference

LONDON, ONTARIO--(Marketwire - August 11, 2010) - Stellar Pharmaceuticals Inc. (OTCBB: SLXCF) (“Stellar” or “the Company”), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced that its President and Chief Executive Officer, Peter Riehl, is scheduled to present an update of the Company’s business at the upcoming 2010 Southern California Investor Conference sponsored by Global Hunter Securities. The conference will be held in Newport Beach, CA, with Mr. Riehl’s presentation scheduled for 10:00 a.m. PDT (1:00 p.m.), on August 17, 2010.

A live audio webcast of Mr. Riehl’s presentation will be available on the investor relations section of the Company’s website at www.stellarpharma.com.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc® and NeoVisc Single Dose, for symptomatic treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis /painful bladder syndrome (IC/PBS), an inflammatory disease of the urinary bladder wall. Stellar also has an in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company’s website at www.stellarpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company’s business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company’s filings.